Soros Fund Management LLC lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 23.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 150,000 shares of the company's stock after selling 44,776 shares during the quarter. Soros Fund Management LLC owned 0.15% of Neurocrine Biosciences worth $17,283,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also added to or reduced their stakes in NBIX. State Street Corp lifted its position in Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company's stock valued at $593,186,000 after acquiring an additional 539,936 shares during the period. Renaissance Technologies LLC grew its position in Neurocrine Biosciences by 9.6% during the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company's stock valued at $339,790,000 after buying an additional 216,500 shares during the period. AQR Capital Management LLC grew its position in Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company's stock valued at $166,959,000 after buying an additional 228,444 shares during the period. Bank of New York Mellon Corp grew its position in Neurocrine Biosciences by 1.4% during the second quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company's stock valued at $128,639,000 after buying an additional 13,069 shares during the period. Finally, Braidwell LP grew its position in Neurocrine Biosciences by 20.9% during the third quarter. Braidwell LP now owns 917,674 shares of the company's stock valued at $105,734,000 after buying an additional 158,665 shares during the period. Institutional investors own 92.59% of the company's stock.
Neurocrine Biosciences Stock Up 1.5 %
Neurocrine Biosciences stock traded up $1.95 during mid-day trading on Friday, hitting $128.37. The company had a trading volume of 188,361 shares, compared to its average volume of 868,445. The stock has a market cap of $13.00 billion, a price-to-earnings ratio of 33.89 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The business has a fifty day moving average of $120.07 and a 200 day moving average of $131.19.
Insider Buying and Selling at Neurocrine Biosciences
In related news, insider Jude Onyia sold 2,331 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares of the company's stock, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.30% of the stock is currently owned by insiders.
Analyst Ratings Changes
NBIX has been the subject of a number of recent analyst reports. Barclays dropped their price target on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a research report on Monday, September 9th. StockNews.com lowered shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 1st. Raymond James restated an "outperform" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Royal Bank of Canada dropped their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a research report on Friday, October 4th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and an average target price of $163.91.
Check Out Our Latest Stock Analysis on Neurocrine Biosciences
About Neurocrine Biosciences
(
Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See Also
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
